Mammo Responsibility Ups Screening; Opioids for Cancer Pain? Ignored Signs of CRC

Women who scheduled their own mammograms were more likely to complete the screening process. (Penn Medicine, American Journal of Preventive Medicine)

With the blessings of the EU and Spanish health authorities, cancer specialists at a Barcelona hospital cooked up their own CAR T-cell therapy, which costs a third of the marketed brands. (STAT)

Sanofi announced it will terminate clinical development of the antibody-drug conjugate tusamitamab ravtansine following a negative outcome in a trial of second-line treatment for non-small cell lung cancer.

A trial of the radiopharmaceutical 177Lu-PNT2002 in advanced prostate cancer met the primary endpoint of progression-free survival, but showed an early survival trend favoring the control group, Lantheus and POINT Biopharma announced.

North Carolina has sued HCA Healthcare, alleging the for-profit system failed to keep promises to maintain consistent and high-quality oncology and emergency services following the 2019 acquisition of Mission Health System in Asheville.

The value of opioid analgesics for cancer-related pain requires reappraisal, given “the limited quality and quantity of research,” according to authors of a review. (CA: A Cancer Journal for Clinicians)

Colorectal cancer (CRC) screening is more effective than previously recognized, according to a reanalysis of clinical trial data. (MIT News)

People who developed CRC in their 20s and 30s share their experiences and the warning signs they ignored. (NBC News)

New insights into the continuing increase in endometrial cancer incidence and mortality, which disproportionately affects Black women. (Memorial Sloan Kettering Cancer Center)

The combination of a cancer vaccine and an immune checkpoint inhibitor reduced the risk of melanoma recurrence or death by 49% at 3 years. (CNBC)

Three of the first six patients with advanced melanoma that progressed on immune checkpoint inhibition responded to an investigational tumor-infiltrating lymphocyte cellular therapy and all six had disease control, Obsidian Therapeutics announced.